Many studies have linked elevated MCP-1 serum levels in patients with the presence, development, or recurrence of solid tumors, including advanced HNSCC, with significant lower overall survival (OS) and tumor-specific survival (TSS), indicating MCP-1 as a prognostic biomarker for solid tumors including HNSCC and clinical outcome [14]. This evidence concerns the gene CCL2 and head and neck squamous cell carcinoma.